West Pharmaceutical Services (WST) Long-Term Deferred Tax (2009 - 2026)

West Pharmaceutical Services (WST) has reported Long-Term Deferred Tax for 18 consecutive years, with $72.3 million the latest figure, recorded in Q2 2026.

• Quarterly Long-Term Deferred Tax rose 143.43% year-over-year to $72.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $72.3 million (up 143.43% YoY) and the FY2025 annual result came in at $38.4 million, up 47.69% from the prior year.
• Long-Term Deferred Tax grew to $72.3 million in Q2 2026 per WST's latest filing, from $63.9 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for WST reached as high as $99.0 million in Q1 2023 and fell as low as $17.3 million in Q3 2023.
• A 5-year average of $46.1 million and a median of $38.0 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax plunged 78.79% — and 2026, when it surged 145.77%.
• Year by year, Long-Term Deferred Tax stood at $65.6 million in 2022, then slumped by 60.82% to $25.7 million in 2023, then gained by 1.17% to $26.0 million in 2024, then soared by 47.69% to $38.4 million in 2025, then soared by 88.28% to $72.3 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $72.3 million, $63.9 million, and $38.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.